Alithea Genomics, an emerging leader in the field of large-scale RNA sequencing and transcriptomics, announced the closing of its seed financing round with an additional CHF 3 million ($3.9 million), led by Genku Ventures and joined by Novalis Biotech and Zürcher Kantonalbank as well as several private investors. This additional funding brings the total seed round to CHF 6.9 million ($8.9 million). The proceeds will be used primarily to accelerate commercialization of its new 1536‑well MERCURIUSTM DRUG-seq kits unlocking greater potential of using cell transcriptomics in primary drug screening and exploratory toxicology. These applications, previously out of reach due to cost and throughput constraints, can now be addressed by scaling 3′RNA‑seq library preparation to 1,536 samples. Alithea will also invest the proceeds in accelerating new technology development and building proprietary transcriptomic data assets to fuel the industry’s AI/ML initiatives.
